US Department of Defense
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From US Department of Defense
The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders. The allure comes from VA’s strong analytics and data crunching capabilities as well as its investigatory and trial management expertise in high-profile areas like traumatic brain injury, post-traumatic stress and major depression.
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Manufacturers bracing for CMS' new mandatory bundled payment program for total hip and knee replacement surgery may be able to breathe a sigh of relief as hospitals are expected to target post-acute-care rather than implants to bring down costs. Amid these changes, orthopedic manufacturers are helping hospitals address bundled payments by developing innovative solutions that improve procedural efficiencies, recovery times, costs and patient outcomes, including outpatient total joint surgery, robotics, custom implants, and patient-specific instrumentation.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.